Eddingpharm Acquires China Rights to Insomnia Drug from Australia's Suda

Shanghai's Eddingpharm in-licensed China rights to ZolpiMist® from Suda, an Australian drugmaker specializing in oro-mucosal delivery of drugs. ZolpiMist is a reformulation of zolpidem tartrate (Ambien), a short-term treatment for insomnia, delivered via Suda's OroMist® drug delivery platform. Eddingpharm will pay $300,000 upfront and another $200,000 once the product passes CFDA registration testing. Eddingpharm estimates the deal will generate $26 million of revenues for Suda over 15 years. More details.... Stock Symbol: (ASX: SUD) Share this with colleagues: // //